Addiction

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Retrieved on: 
Thursday, February 29, 2024
Mental Health, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Therapy, Addiction, Anxiety, Artificial intelligence, CNS, Patient, IND, Depression, Pharmaceutical industry

The compounds come from Enveric’s extensive library of over 1,000 novel molecules generated using the Company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™).

Key Points: 
  • The compounds come from Enveric’s extensive library of over 1,000 novel molecules generated using the Company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™).
  • The three term sheets contemplate that the undisclosed licensee would receive exclusive, royalty-bearing global licenses to develop and sublicense the assets, along with cash buyout options and future option rights to substantially related assets in the Enveric portfolio.
  • The licensee would assume responsibility for all future preclinical and clinical development for all human and/or animal pharmaceutical applications.
  • The compound classes under the term sheets come from two of the seven portfolios of preclinical molecules that Enveric recently unveiled as available for out-licensing .

Empatica Reveals Next Generation FDA-Cleared Epilepsy Watch and Launches AI Seizure Forecasting Study

Retrieved on: 
Wednesday, February 28, 2024
Hardware, FDA, Health Technology, Data Management, Consumer Electronics, Technology, Apps, Applications, Managed Care, Medical Devices, Neurology, Hospitals, Artificial Intelligence, Biotechnology, Nursing, Health, Mobile, Wireless, Algorithm, Caregiver, Multimedia, Generalized tonic–clonic seizure, AI, Forecasting, NASA, Quality of life, Sleep, Seizure, SMS, HHS, System, Migraine, Patient, Epilepsy, Trial of the century, Research, Addiction, Depression, Pharmaceutical industry

Empatica, a leader in remote health monitoring powered by AI, is proud to announce the official launch of EpiMonitor , the latest advancement in wearable epilepsy monitoring.

Key Points: 
  • Empatica, a leader in remote health monitoring powered by AI, is proud to announce the official launch of EpiMonitor , the latest advancement in wearable epilepsy monitoring.
  • In December 2023, Empatica also announced plans to conduct a groundbreaking study to develop a seizure forecasting algorithm, based on the world’s largest real-world data set in epilepsy patients.
  • “Our FORESIGHT clinical study is an incredibly exciting opportunity to advance personalized seizure forecasting,” said Dr. Marisa Cruz, Empatica’s Chief Medical Officer.
  • In 2018, Empatica’s Embrace wearable received FDA clearance for seizure monitoring, making it the world's first epilepsy watch to be cleared by the FDA.

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Retrieved on: 
Friday, February 23, 2024
Mental Health, Managed Care, General Health, Neurology, Science, Nursing, Clinical Trials, Natural Resources, Biotechnology, Alternative Medicine, Tobacco, Health, Research, Cannabis, Retail, Pharmaceutical, Oncology, Therapy, Addiction, Anxiety, MDMA, Patent, Patient, IP, Hallucination, Mescaline, Cannabidiol, Cancer, Depression, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.
  • The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer.
  • The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea.
  • Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

ASTHO Appoints Joseph Kanter, MD, MPH, as New Chief Executive Officer

Retrieved on: 
Monday, March 4, 2024
LDH, Multimedia, Addiction, City, Naloxone, MBA, Sound, Health, COVID-19, History, Tulane University, Public, Policy, MPH, Medicine, Health equity, Homelessness, State, Infection, Environment, Partnership, Nursing

ARLINGTON, Va., March 4, 2024 /PRNewswire/ -- The Association of State and Territorial Health Officials (ASTHO) today announced that Joseph Kanter, MD, MPH, has been named as the organization's chief executive officer, effective April 8, 2024.

Key Points: 
  • ARLINGTON, Va., March 4, 2024 /PRNewswire/ -- The Association of State and Territorial Health Officials (ASTHO) today announced that Joseph Kanter, MD, MPH, has been named as the organization's chief executive officer, effective April 8, 2024.
  • Dr. Kanter, a board-certified emergency physician, brings a wealth of experience to ASTHO including prior public service as both a Louisiana state health officer and municipal health director.
  • Dr. Kanter joins ASTHO from the Louisiana Department of Health (LDH) where he served as state health officer and medical director from January 2021 - February 2024.
  • ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.

Voices for Non-Opioid Choices Coalition Applauds Introduction of Alternatives to PAIN Act in Senate

Retrieved on: 
Thursday, February 29, 2024
PAIN, Opioid, Addiction, Pain, Drug, Risk, House, Pain management, Medicare, Patient, Medicare Part D, Representative, Alternatives, Senate, Health insurance

WASHINGTON, Feb. 29, 2024 /PRNewswire/ -- Today, the Senate took a crucial step forward in the fight to prevent opioid addiction by introducing the bipartisan Alternatives to Prevent Addiction in the Nation (PAIN) Act. The Alternatives to PAIN Act will ensure that all Americans can access safe, effective, non-addictive pain management approaches. In the process, the Alternatives to PAIN Act can prevent opioid addiction that occurs following an acute pain incident and save lives.

Key Points: 
  • The Alternatives to PAIN Act will ensure that all Americans can access safe, effective, non-addictive pain management approaches.
  • In the process, the Alternatives to PAIN Act can prevent opioid addiction that occurs following an acute pain incident and save lives.
  • "Over one million American seniors are diagnosed with opioid addiction every year," said Chris Fox, Executive Director of the Voices for Non-Opioid Choices Coalition .
  • In January, Representative Mariannette Miller-Meeks (R-IA) and Representative Tony Cárdenas (D-CA) introduced companion legislation, The Alternatives to PAIN Act (H.R.

'An Urgent Public Health Necessity' - National Institute for Play Releases New Report Underlining Science and Power of Play

Retrieved on: 
Thursday, February 29, 2024
Grammatical mood, Foreword, Anxiety, Emotion, Multimedia, Socialization, Vocabulary, Sleep, Loneliness, Storyteller, Pleasure, Depression, Heart, Mevalonate pathway, Imagination, Competition, Biology, Addiction, Travel, Brain, Pharmaceutical industry

The free report, entitled The Power of Play: Losing and Finding Ourselves through Everyday Play, advances the understanding that play is proven to lead to healthier, happier lives.

Key Points: 
  • The free report, entitled The Power of Play: Losing and Finding Ourselves through Everyday Play, advances the understanding that play is proven to lead to healthier, happier lives.
  • Its authors, Scott G. Eberle, Ph.D., and Stuart Brown, M.D., have spent decades studying the impact of play on the human condition.
  • It collectively asserts that the diminishing presence of play in our daily lives is an urgent public health matter.
  • Ancient in its origins, play is core to the human experience and is engrained in all of us.

'An Urgent Public Health Necessity' - National Institute for Play Releases New Report Underlining Science and Power of Play

Retrieved on: 
Thursday, February 29, 2024
Grammatical mood, Foreword, Anxiety, Emotion, Socialization, Vocabulary, Sleep, Loneliness, Storyteller, Pleasure, Depression, Heart, Mevalonate pathway, Imagination, Competition, Biology, Addiction, Travel, Brain, Pharmaceutical industry

The free report, entitled The Power of Play: Losing and Finding Ourselves through Everyday Play, advances the understanding that play is proven to lead to healthier, happier lives.

Key Points: 
  • The free report, entitled The Power of Play: Losing and Finding Ourselves through Everyday Play, advances the understanding that play is proven to lead to healthier, happier lives.
  • Its authors, Scott G. Eberle, Ph.D., and Stuart Brown, M.D., have spent decades studying the impact of play on the human condition.
  • It collectively asserts that the diminishing presence of play in our daily lives is an urgent public health matter.
  • The report was produced by NIFP with support by Visit California and contributors Anthony Christopher, Lauren Sundstrom, Bowen F. White, and Tom Norquist.

Matter Neuroscience Secures $26M in Funding to Cure Unhappiness

Retrieved on: 
Tuesday, February 27, 2024
Neuroimaging, DEPT, Happiness, Diagnosis, Anxiety, Mental health, Interventional radiology, Emotion, Research, Biomedical engineering, Professor, Collaborative Fund, Capitalism, Polaris Partners, Capital, Imaging, Neurology, Risk, Trial of the century, Health, Human Brain Project, Medical imaging, Brain mapping, ARCH, Bayer, Bouchon, Maastricht University, Biological engineering, Psychiatry, Science, Magnetic resonance, ARCH Venture Partners, Good Worldwide, Addiction, Brain, Depression

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Matter Neuroscience, the company working to unlock a deeper understanding of happiness and well-being by providing people with personalized insights into their brain chemistry emerges from stealth mode today. Matter announced it has received $26 million in funding, initial funding seeded by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures, and joined by Collaborative Fund and others. With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.

Key Points: 
  • With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.
  • Together with its collaboration partners, Matter Neuroscience will initiate three more clinical studies in 2024.
  • Matter also offers users access to educational materials and a lecture series on the neuroscience of happiness.
  • Matter Neuroscience was co-founded in 2019 with Ben Goldhirsh of GOOD Worldwide and the Goldhirsh Foundation, and Chris Shiflett of Faculty and Brooklyn Beta.

Alexandria Real Estate Equities, Inc. Continues Its Distinctive, Steadfast and Positive Impact on the Widespread and Complex Mental Health Crisis

Retrieved on: 
Tuesday, February 27, 2024
DSM-IV codes, Mental health, FDA, Suicide, Injury, Mental, Mental disorder, Social responsibility, Health, Attention, Human, Biomarker, Therapy, Ecosystem, Public, Policy, Depression, AAA, National Alliance, Patient, Veteran, Military personnel, Congress, Navy, Heart, Trauma, Alexandria Real Estate Equities, Investment, Addiction, Biogen, Partnership, Nursing

PASADENA, Calif., Feb. 27, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, continues to make a distinctive, steadfast and positive impact on the widespread and complex mental health crisis through one of the company's bedrock social responsibility pillars that prioritizes this unprecedented crisis. With more than 1 in 5 American adults living with a mental illness and over 50,000 suicides in the United States in 2023, including over 6,000 veterans who die by suicide annually, the nation's shared societal responsibility to drive forward treatments and solutions to this devastating public health challenge is immense. The National Alliance on Mental Illness estimates that untreated mental illness represents an economic burden to the nation of over $300 billion each year — a number that understates the true costs of these conditions for those afflicted as well as for their families and society.

Key Points: 
  • "The staggering yet often overlooked mental health crisis in our country is the defining public health challenge of our time.
  • Our Alexandria Summit on Mental Health will set an agenda to drive significant reform, catalyze new mission-critical public-private partnerships and influence policy to accelerate innovation that saves lives."
  • Mental health issues often co-occur with substance use issues, with roughly 50 percent of individuals with severe mental disorders also impacted by addiction.
  • Military personnel and veterans experience mental health and addiction issues at dramatically higher rates than the general U.S. population.